Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

News

Anatara Lifesciences Ltd (ASX:ANR) Announces Australian Patent Grant for Detach

🕔4/16/2021 9:15:44 AM 372

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled "Anti-diarrhea formulation which avoids antimicrobial resistance".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Market Update

🕔4/7/2021 10:34:56 AM 1050

Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Completion of Unmarketable Parcel Share Buy-Back

🕔2/10/2021 8:51:29 AM 1647

On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives Ethics Approval to Start IBS Trial

🕔2/8/2021 9:42:00 AM 1273

Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) R&D Tax Incentive Received

🕔2/3/2021 9:33:37 AM 1269

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful Poultry Trial

🕔2/1/2021 8:52:29 AM 1305

Anatara Lifesciences (ASX:ANR) is pleased to announce successful completion of the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Cash Report

🕔1/28/2021 10:13:28 AM 1253

Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.68m.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Human Health Update

🕔12/8/2020 8:57:08 AM 2475

Anatara Lifesciences (ASX:ANR) is pleased to advise that it is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon-targeted formulation (3FDC).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders and Presentation

🕔11/26/2020 10:51:01 AM 2427

The last twelve months have seen exciting developments as Anatara Lifesciences Ltd (ASX:ANR) advances our lead human health product, our Gastrointestinal ReProgramming (GaRP) complementary medicine.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Animal Health Update

🕔11/18/2020 8:52:00 AM 2246

Anatara Lifesciences (ASX:ANR) is pleased to provide an update on challenge trials of select Anatara animal health assets.

Read Full Article
###

66,190 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 718) (Last 30 Days: 1625) (Since Published: 66190) 

Company Data

    Headquarters
  • Level 3, 62 Lygon Street
    Carlton South, VIC, 3053
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports